Paul E. Wakely
Impact in
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Cancer-related molecular mechanisms research
- Breast Cancer Treatment Studies
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
Papers in
-
- Sarcoma Diagnosis and Treatment 65
- Rheumatology 32
- Soft tissue tumor case studies 14
- Bone Tumor Diagnosis and Treatments 12
- Co-authors
- William Jackson Frable (18 shared papers)Joel L. Mayerson (15 shared papers)Syed Zulfiqar Ali (25 shared papers)Saul M. Suster (5 shared papers)Jeffrey S. Kneisl (4 shared papers)Matthew David Ringel (7 shared papers)Motoyasu Saji (6 shared papers)Richard T. Kloos (3 shared papers)
- Journals
- Cancer Cytopathology (20 papers)Cancer (17 papers)Diagnostic Cytopathology (15 papers)American Journal of Clinical Pathology (12 papers)Cell Reports (11 papers)
- Partner nations
- United StatesCanadaItaly
In The Last Decade
Paul E. Wakely
246 papers receiving 28.3k citations
Paul E. Wakely's Hit Papers
Peers
Comparison fields: 5 of 149
- Cancer Research 6.6k
- Oncology 7k
- Otorhinolaryngology 869
- Pulmonary and Respiratory Medicine 4.5k
- Molecular Biology 7.2k
Countries citing papers authored by Paul E. Wakely
This map shows the geographic impact of Paul E. Wakely's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul E. Wakely with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul E. Wakely more than expected).
Fields of papers citing papers by Paul E. Wakely
This network shows the impact of papers produced by Paul E. Wakely. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul E. Wakely. The network helps show where Paul E. Wakely may publish in the future.
Co-authors
The 25 scholars most cited alongside Paul E. Wakely, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 258 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The Immune Landscape of Cancer Hit paper breakdown → | 2018 | 4385 |
| 2 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics Hit paper breakdown → | 2018 | 2633 |
| 3 | Oncogenic Signaling Pathways in The Cancer Genome Atlas Hit paper breakdown → | 2018 | 2371 |
| 4 | Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Hit paper breakdown → | 2018 | 1758 |
| 5 | Comprehensive Characterization of Cancer Driver Genes and Mutations Hit paper breakdown → | 2018 | 1748 |
| 6 | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Hit paper breakdown → | 2018 | 1634 |
| 7 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Hit paper breakdown → | 2018 | 824 |
| 8 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy Hit paper breakdown → | 2018 | 768 |
| 9 | Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients Hit paper breakdown → | 2018 | 696 |
| 10 | Pathogenic Germline Variants in 10,389 Adult Cancers Hit paper breakdown → | 2018 | 617 |
| 11 | Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines Hit paper breakdown → | 2018 | 598 |
| 12 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma Hit paper breakdown → | 2018 | 580 |
| 13 | A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers Hit paper breakdown → | 2018 | 470 |
| 14 | Driver Fusions and Their Implications in the Development and Treatment of Human Cancers Hit paper breakdown → | 2018 | 457 |
| 15 | The Immune Landscape of Cancer Hit paper breakdown → | 2019 | 455 |
| 16 | Phase II Trial of Sorafenib in Metastatic Thyroid Cancer Hit paper breakdown → | 2009 | 454 |
| 17 | lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer Hit paper breakdown → | 2018 | 394 |
| 18 | Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer Hit paper breakdown → | 2018 | 384 |
| 19 | 2018 | 378 | |
| 20 | 2018 | 349 |
About Paul E. Wakely
Paul E. Wakely is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology, Pathology and Forensic Medicine, Surgery and Oncology, having authored 258 papers that have together received 28.9k indexed citations. Recurring topics across this work include Sarcoma Diagnosis and Treatment (65 papers), Thyroid Cancer Diagnosis and Treatment (20 papers), Salivary Gland Tumors Diagnosis and Treatment (19 papers), Lymphoma Diagnosis and Treatment (16 papers), Cancer Genomics and Diagnostics (15 papers), Soft tissue tumor case studies (14 papers), Bone Tumor Diagnosis and Treatments (12 papers) and Head and Neck Cancer Studies (11 papers). The work is most often cited by research in Cancer Research (6.6k citations), Oncology (7k citations), Otorhinolaryngology (869 citations), Pulmonary and Respiratory Medicine (4.5k citations) and Molecular Biology (7.2k citations). Paul E. Wakely has collaborated with scholars based in United States, Canada and Italy. Frequent co-authors include William Jackson Frable, Joel L. Mayerson, Syed Zulfiqar Ali, Saul M. Suster, Jeffrey S. Kneisl, Matthew David Ringel, Motoyasu Saji, Richard T. Kloos, Jan F. Silverman and Manisha H. Shah. Their work appears in journals such as Cancer Cytopathology, Cancer, Diagnostic Cytopathology, American Journal of Clinical Pathology and Cell Reports.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.